Keyphrases
Metastatic Breast Cancer
100%
Antiprogestins
100%
ER +
40%
Endocrine Therapy
40%
Endocrine Resistance
40%
Clinical Trials
20%
Cell Proliferation
20%
Potential Treatments
20%
Treatment Options
20%
Targeted Therapy
20%
Phosphoinositide 3-kinase (PI3K)
20%
Estrogen Receptor
20%
Progesterone Receptor
20%
Functional Imaging
20%
MTOR Inhibitor
20%
Hormone Receptor-positive
20%
Gene mutation
20%
Targeted Treatment
20%
PI3K Inhibitor
20%
Human Epidermal Growth Factor Receptor 2-negative
20%
Treatment Combination
20%
HER2 Metastatic Breast Cancer
20%
Cytotoxic Therapy
20%
Multi-target
20%
Estrogen Receptor 1 (ESR1)
20%
Mammary Tissue
20%
ERBB2 Gene
20%
Cyclin-dependent Kinase (CDK) 4/6 Inhibitors
20%
Medicine and Dentistry
Metastatic Breast Cancer
100%
Antigestagen
100%
Hormone Therapy
40%
Cyclin-Dependent Kinase
40%
Disease
20%
Clinical Study
20%
Clinical Trial
20%
Targeted Therapy
20%
Functional Imaging
20%
Cell Proliferation
20%
Gamma Urogastrone
20%
Epidermal Growth Factor Receptor 2
20%
Phosphoinositide 3-Kinase
20%
Gene Mutation
20%
Cytotoxic Chemotherapy
20%
Phosphoinositide 3-Kinase Inhibitor
20%
Mammalian Target of Rapamycin Inhibitor
20%
Estrogen Receptor
20%
Progesterone Receptor
20%
Estrogen Receptor Alpha
20%
Hormone Receptor
20%
Pharmacology, Toxicology and Pharmaceutical Science
Metastatic Breast Cancer
100%
Antigestagen
100%
Endocrine Therapy
40%
Clinical Trial
20%
Preclinical Study
20%
Estrogen Receptor
20%
Clinical Study
20%
Cytotoxic Chemotherapy
20%
Mammalian Target of Rapamycin Inhibitor
20%
Cyclin Dependent Kinase
20%
Phosphatidylinositol 3 Kinase
20%
Gamma Urogastrone
20%
Phosphatidylinositol 3 Kinase Inhibitor
20%
Epidermal Growth Factor Receptor 2
20%
Disease
20%
Progesterone Receptor
20%
Hormone Receptor
20%
Estrogen Receptor Alpha
20%